Search the Newsreel

Pharma-Zahlen im Kontrast: BioNTech schockt mit Prognose - Pfizer schafft die Überraschung

Pfizer Post Loss on Higher Revenue

Pfizer reported a second-quarter loss of $248 million, or 4 cents a share, despite a 3% increase in revenue to $15.03 billion. The company's revenue growth was driven by its oncology business, which helped to offset declining sales of its Covid-19 products. This contrasts …

Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings

Pfizer beats earnings forecasts for the second quarter, while BioNTech’s results miss expectations due to weak Covid vaccine demand. Continue Reading

Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance

Focused Execution Drove 18% Operational Revenue Growth of Launched and Acquired Products(1) Advancing Robust Late-Stage Pipeline, with Several Key Pivotal Readouts Expected Over Next 12 Months Announces Expansion of Productivity Enhancement Initiatives NEW YORK, August 04, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results …

Caterpillar, Pfizer and 3 Stocks to Watch Heading Into Tuesday

As U.S. stock futures trade higher, several companies are poised for investor attention on Tuesday. Caterpillar (NYSE: CAT) and McDonald's (NYSE: MCD) are expected to report quarterly earnings, while Palantir Technologies (NASDAQ: PLTR), Snap Inc (NYSE: SNAP), and Pfizer Inc (NYSE: PFE) have already …

Pfizer raises revenue outlook after quarterly earnings top estimates

Pfizer beat Wall Street expectations for its second-quarter 2026 earnings and raised its full-year revenue guidance midpoint. The company reported adjusted earnings of $0.77 per share and revenue of $15.03 billion, driven by growth in new and acquired products, which offset declines in its …

Pfizer (PFE) Q2 Earnings and Revenues Top Estimates

Pfizer tops estimates, hikes low end of revenue guidance on strength of Eliquis, other drugs

Pfizer eleva su previsión de ventas para 2026 tras sólidos resultados trimestrales

Pfizer’s Quarterly Results Beat Expectations on Cancer, Heart Drugs

OppFi: Look Beyond Q2, As Greenlighting Of The BNC Deal Is Not Certain (NYSE:OPFI)

Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S Revenue Breakdown – NEO:PFE

This article provides a revenue breakdown for Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S (NEO:PFE). It highlights that the United States was the primary contributor to the company's revenue, generating ‪51.81 billion CAD last year and ‪53.01 billion CAD …

July Social Media Round-Up—America 250, Pfizer Futures, and More

This article provides a round-up of Pfizer's social media activities in July, highlighting various discussions, achievements, and scientific insights. It covers topics like living with alopecia areata, a Pfizer colleague's cancer survival story, and reflections on scientific advancements. The summary also notes leadership updates, …

Pfizer (PFE) Q2 Earnings: What To Expect

Pfizer (PFE) Q2 Earnings: What To Expect Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting earnings this Tuesday before market hours. Here's what to expect. Pfizer beat analysts' revenue expectations last quarter, reporting revenues of $14.45 billion, up 5.4% year on year. It was …

ETFs Investing in Pfizer Inc Shs Cert Deposito Arg Repr 0.25 Shs Stocks

This article lists ETFs that hold Pfizer Inc Shs Cert Deposito Arg Repr 0.25 Shs stocks, highlighting one specific fund: the CTBC Global High Dividend ETF Securities Investment Trust Fund. It provides financial details such as market value, weight, issuer, management style, expense ratio, …

Pfizer (PFE) Stock Looks Reasonable Based On Today’s Broader Checks

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Pfizer stock has declined 27.7% over the past 5 years, yet the current valuation checks and market multiples now point to a picture that looks …

Vanguard Capital Management (OPFI) discloses 2.87% OppFi stake in amended filing

Vanguard Capital Management has filed an amended ownership report revealing a 2.87% beneficial ownership stake in OppFi Inc. common stock as of June 30, 2026. This translates to 2,456,441 shares, with Vanguard exercising sole voting power over 239,649 shares and sole dispositive power over …

Pfizer Yields 6.8%, Trades at 8.5X Earnings, and Has a Promising Late-Stage Weight Loss Drug. Why Are So Many Investors Still Ignoring the Stock?

Pfizer offers an attractive 6.8% dividend yield and trades at 8.5x forward earnings, with a promising late-stage weight loss drug in its pipeline. Despite these positives, its stock has been stagnant due to recent negative revenue growth and upcoming patent expirations for key products …

Pfizer (NYSE: PFE) Offers Value And Income While Eli Lilly (NYSE: LLY) Bets On Growth In Diverging Pharma Investment Race

Pfizer (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) offer unique divergent investment opportunities in the pharmaceutical industry. While one acts as a value and income play, the other stands out as a solid growth investment supported by rapid expansion in obesity and diabetes franchises. …

Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this drugmaker have returned …

Pfizer Stock Forecast: 15% Upside as Its Pipeline Delivers New Wins

Pfizer Prepares Global Regulatory Litfulo Filings Following Skin Pigment Improvements In Late-Stage Trial

Pfizer has announced positive topline data from two Phase 3 clinical trials for LITFULO, its once-daily treatment for nonsegmental vitiligo (NSV). The trials showed significant improvements in skin repigmentation, leading Pfizer to prepare global regulatory submissions for the drug. LITFULO, previously approved for severe …

Pfizer’s oral drug restores skin pigmentation in late-stage vitiligo trials

Pfizer announced that its oral drug Litfulo successfully restored skin pigmentation in patients with nonsegmental vitiligo during two late-stage trials. The drug significantly improved facial and total-body repigmentation, paving the way for global regulatory submissions. Litfulo, which blocks specific immune cell proteins, is already …

Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo

Pfizer announced positive topline results from two Phase 3 trials (TRANQUILLO and TRANQUILLO 2) evaluating LITFULO (ritlecitinib) for nonsegmental vitiligo (NSV). The studies demonstrated significant improvements in facial and total body repigmentation compared to placebo, meeting their co-primary endpoints. Based on these findings, Pfizer …

Pfizer Inc. (PFE) vs. Eli Lilly and Company (LLY): The Growth vs. Value Play in Pharma

This article analyzes Pfizer (PFE) and Eli Lilly (LLY) as contrasting investment opportunities within the pharmaceutical sector. Pfizer is presented as a value and income play due to its low valuation and high dividend yield, despite challenges like declining COVID-19 product sales and patent …

Pfizer (PFE) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates

Pfizer (PFE) Wins EU Approval For Updated COVID Vaccine Ahead Of 2026 Season

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. European Commission grants marketing authorization for Pfizer and BioNTech's XFG-adapted COVID-19 vaccine for the 2026-2027 season in the EU. Approval covers use in …

EU Approves Pfizer, BioNTech XFG COVID-19 Vaccine

The European Commission has granted marketing authorization for Pfizer and BioNTech's 2026-2027 COVID-19 vaccine, targeting the XFG variant, for individuals aged 6 months and older. This approval follows the EMA's recommendation to update vaccines to better protect against the XFG variant of the JN.1 …

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

Data indicate that the 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, induces a strong immune response against contemporary circulating and emerging lineages More than five billion doses of the Pfizer-BioNTech COVID-19 vaccines distributed globally Vaccine demonstrates a favorable safety and efficacy profile Shipping …

EU Authorizes Pfizer-BioNTech COVID Vaccine for Ages 6 Months+

The European Commission has granted marketing authorization for Pfizer and BioNTech's 2026-2027 monovalent XFG-adapted COVID-19 vaccine for individuals aged 6 months and older. This authorization, valid across 30 European countries, follows recommendations to target the XFG variant and is supported by data showing strong …

Pfizer Stock Ahead of Q2 Earnings: To Buy or Not to Buy?

Pfizer PFE is set to report its second-quarter 2026 earnings on Aug. 4, before market open. The Zacks Consensus Estimate for sales and earnings for the second quarter is pegged at $14.45 billion and 68 cents per share, respectively. Estimates for Pfizer's 2026 earnings …

Pfizer's PREVNAR 20™ Selected for Québec's Publicly Funded Pediatric Pneumococcal Immunization Program

Pfizer's PREVNAR 20™, a 20-valent pneumococcal conjugate vaccine, has been chosen for Québec's publicly funded pediatric immunization program, making it the second Canadian province to adopt it. This initiative aims to provide broader serotype coverage against severe pneumococcal disease in infants and children. Healthcare …

OppFi (OPFI) Expected to Announce Earnings on Wednesday

Why Did OppFi (NYSE:OPFI) Announce Its Next Earnings Call?

Pfizer Number of Employees 2026 | Employee Count & Headcount Data

Pfizer Inc. had approximately 75,157 employees worldwide as of March 2026, marking an 8.3% decline from 2023. Despite the overall headcount reduction, Pfizer is actively hiring, with 2,887 active job postings in 2026, a 49.7% increase from the previous year. The company's workforce is …

Pfizer (PFE): Company Profile, Stock Price, News, Rankings

This article provides a company profile for Pfizer (PFE), detailing its business in developing medications and vaccines across various therapeutic areas, with a significant focus on oncology. It highlights key strategic moves such as the acquisition of Seagen and re-entry into the obesity market, …